Injury induced by chemical warfare agents: characterization and treatment of ocular tissues exposed to nitrogen mustard
- PMID: 12824239
- DOI: 10.1167/iovs.02-1164
Injury induced by chemical warfare agents: characterization and treatment of ocular tissues exposed to nitrogen mustard
Abstract
Purpose: Mustard agents are highly toxic and abundant warfare chemicals, primarily affecting ocular tissues, with no specific treatment antidote. The purpose of the present study was to examine the efficacy of novel metallocomplexes, known to inhibit the formation of highly reactive free radicals, to reduce ocular injury induced by nitrogen mustard (NM).
Methods: One eye in each of 72 rabbits was exposed to 1% to 2% NM. Topical treatment with eye drops of a metallocomplex--either zinc- or gallium-desferrioxamine (Zn/DFO and Ga/DFO)--was compared with treatment with saline, zinc (chloride), or DFO alone. Examiners masked to the treatment groups assessed the extent of ocular injury and the response to treatment using clinical, histologic, and biochemical criteria.
Results: Exposure to NM followed by administration of carrier alone (saline) caused severe and long-lasting injury to ocular anterior segment structures. Treatment with either Zn/DFO or Ga/DFO yielded marked protection (52%-64%), including faster healing of corneal epithelial erosions, less scarring and neovascularization, decreased inflammation in the anterior chamber, better maintenance of intraocular pressure, and less severe changes in the iris and lens. These were also associated with better preservation of systemic antioxidant status. Zinc or DFO alone afforded lower levels of protection. No toxic effects of these complexes were observed.
Conclusions: It is suggested that Zn/DFO or Ga/DFO, by virtue of their enhanced ability to infiltrate cells and inhibit transition metal-dependent formation of free radicals through the combined push-pull mechanism, be considered as a basis for treatment of mustard injuries.
Similar articles
-
Treatment of ocular tissues exposed to nitrogen mustard: beneficial effect of zinc desferrioxamine combined with steroids.Invest Ophthalmol Vis Sci. 2005 May;46(5):1640-6. doi: 10.1167/iovs.04-1165. Invest Ophthalmol Vis Sci. 2005. PMID: 15851563
-
Use of amphoteric rinsing solution for treatment of ocular tissues exposed to nitrogen mustard.Acta Ophthalmol. 2013 Feb;91(1):e35-40. doi: 10.1111/j.1755-3768.2012.02533.x. Epub 2012 Oct 5. Acta Ophthalmol. 2013. PMID: 23035792
-
The protective and therapeutic effects of zinc chloride and desferrioxamine on skin exposed to nitrogen mustard.Mil Med. 2003 Aug;168(8):614-7. Mil Med. 2003. PMID: 12943035
-
Ocular effects of exposure to industrial chemicals: clinical management and proteomic approaches to damage assessment.Cutan Ocul Toxicol. 2007;26(3):203-25. doi: 10.1080/15569520701402594. Cutan Ocul Toxicol. 2007. PMID: 17687686 Review.
-
Sulfur mustard-induced ocular surface disorders.Ocul Surf. 2011 Jul;9(3):163-78. doi: 10.1016/s1542-0124(11)70026-x. Ocul Surf. 2011. PMID: 21791191 Review.
Cited by
-
A corneo-retinal hypercitrullination axis underlies ocular injury to nitrogen mustard.Exp Eye Res. 2023 Jun;231:109485. doi: 10.1016/j.exer.2023.109485. Epub 2023 Apr 18. Exp Eye Res. 2023. PMID: 37080381 Free PMC article.
-
Washing with buffered vitamin C after corrosive chemical (sodium hypochlorite) exposure reduces ocular depth of injury.Toxicol In Vitro. 2025 Apr;104:106006. doi: 10.1016/j.tiv.2024.106006. Epub 2024 Dec 31. Toxicol In Vitro. 2025. PMID: 39746384
-
The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent.Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16761-6. doi: 10.1073/pnas.0808608105. Epub 2008 Oct 17. Proc Natl Acad Sci U S A. 2008. PMID: 18931304 Free PMC article.
-
Nitrogen Mustard-Induced Corneal Injury Involves DNA Damage and Pathways Related to Inflammation, Epithelial-Stromal Separation, and Neovascularization.Cornea. 2016 Feb;35(2):257-66. doi: 10.1097/ICO.0000000000000685. Cornea. 2016. PMID: 26555588 Free PMC article.
-
Potential of Application of Iron Chelating Agents in Ophthalmic Diseases.Semin Ophthalmol. 2021 May 19;36(4):157-161. doi: 10.1080/08820538.2021.1887900. Epub 2021 Feb 23. Semin Ophthalmol. 2021. PMID: 33621147 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical